US · LUCD
Lucid Diagnostics Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- New York City, NY 10165
- Website
- luciddx.com
Price · as of 2024-12-31
$1.09
Market cap 146.54M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,229.89 | +112,733.94% |
| Intrinsic Value(DCF) | $0.57 | -47.71% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $3.29 | ||||
| 2022 | $1.55 | $20.72 | $0.00 | $0.00 | $23.91 |
| 2023 | $1.29 | $71.33 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.39 | $1,229.89 | $156.42 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Lucid Diagnostics Inc.'s (LUCD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,229.89
- Current price
- $1.09
- AI upside
- +112,733.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.57
-47.71% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LUCD | Lucid Diagnostics Inc. | $1.09 | 146.54M | +112,734% | -48% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| APYX | Apyx Medical Corporation | $3.27 | 134.17M | +662% | -86% | — | — | -1.69 | 2.80 | 0.83 | -2.79 | -7.60 | 2.80 | 61.04% | -39.18% | -48.78% | -115.17% | -88.10% | -32.70% | 2.73 | -3.19 | 5.26 | 4.40 | -0.42 | 2222.00% | -811.00% | 22461.00% | -47.15% | -1.68 | -87.74% | 0.00% | 0.00% | 0.00% | -2.49 | -2.50 | 0.97 | -0.58 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| IXHL | Incannex Healthcare Limit… | $4.24 | 48.7M | +3,609% | +49% | — | — | -0.39 | 1.35 | 210.33 | -0.07 | -0.04 | 1.35 | 100.00% | -27661.63% | -54517.44% | -381.09% | -1055.21% | -250.09% | 0.02 | -78.51 | 2.86 | 2.82 | 0.31 | 109298.00% | 37870.00% | -2234.00% | -69.22% | -1.79 | -577.00% | 0.00% | 0.00% | 51.39% | -0.14 | -0.26 | 38.46 | -12.32 |
| OWLT | Owlet, Inc. | $11.55 | 184.81M | +401% | +393% | — | — | -5.81 | -3.44 | 0.93 | -6.80 | — | -3.29 | 50.36% | -25.90% | -16.06% | 49.33% | 68.11% | -26.78% | -0.56 | -12.40 | 1.27 | 0.89 | 0.88 | -8168.00% | 4452.00% | -4925.00% | -16.44% | -0.31 | 40.32% | 0.00% | 0.00% | 11.27% | -3.19 | -5.38 | 0.83 | -6.50 |
| RCEL | AVITA Medical, Inc. | $5.03 | 124.96M | +486% | -58% | — | — | -3.02 | -8.82 | 2.05 | -3.30 | — | -6.59 | 82.13% | -58.56% | -67.85% | 799.72% | 463.33% | -71.40% | -0.13 | -8.38 | 0.57 | 0.44 | 0.20 | -2720.00% | 1145.00% | -4647.00% | -21.25% | -0.50 | 344.68% | 0.00% | 0.00% | 27.27% | -3.12 | -4.19 | 1.83 | -10.70 |
| RPID | Rapid Micro Biosystems, I… | $4.33 | 191.92M | +463% | -78% | — | — | -2.22 | 1.38 | 3.71 | -1.28 | — | 1.38 | -0.39% | -177.96% | -167.16% | -48.50% | -155.83% | -38.81% | 0.08 | — | 4.61 | 3.32 | 0.23 | -1148.00% | 2457.00% | -300.00% | -43.71% | -2.51 | -142.09% | 0.00% | 0.00% | 0.00% | -1.19 | -1.31 | 2.12 | -4.66 |
| SCLX | Scilex Holding Company | $8.21 | 70.13M | +4,776% | -41% | — | — | -1.16 | -0.44 | 1.49 | -1.78 | — | -0.35 | 70.51% | -147.37% | -128.66% | 39.83% | 80.83% | -74.96% | -0.20 | -42.48 | 0.16 | 0.11 | -0.52 | -5668.00% | 2107.00% | -19198.00% | 22.92% | 0.07 | -18.75% | 0.00% | 0.00% | 106.43% | -1.43 | 6.16 | 2.10 | -13.47 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| STSS | Sharps Technology, Inc. | $1.73 | 50.16M | — | — | — | — | -0.04 | 0.19 | — | -0.48 | -0.01 | 0.19 | 0.00% | — | — | -187.23% | -159.55% | -97.33% | 1.89 | -4.61 | 0.61 | 0.19 | -0.42 | 78195.00% | — | -2322.00% | -1894.69% | -1.34 | -144.00% | 0.00% | 0.00% | 0.00% | -0.42 | -0.46 | — | -10.43 |
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
- CEO
- Lishan Aklog
- Employees
- 72
- Beta
- 1.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.57 ÷ $1.09) − 1 = -47.71% (DCF, example).